CHARLES RIVER LABORATORIES (CRL) 248.21 +4.96 (+2.04%)
248.21 +4.96 (+2.04%)
US1598641074 - Common Stock - After market: 248.21 0 (0%)
Fundamental Rating
Taking everything into account, CRL scores 4 out of 10 in our fundamental rating. CRL was compared to 66 industry peers in the Life Sciences Tools & Services industry. The financial health of CRL is medium. Also its profitability is quite bad. While showing a medium growth rate, CRL is valued expensive at the moment.
Profitability
Profitability Rating
CRL has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for CRL.
CRL's Return On Equity of 16.61% is in line with the rest of the industry. The industry average Return On Equity is 16.61%.
CRL's Return On Assets of 5.91% is worse than the rest of the industry. The industry average Return On Assets is 8.42%.
CRL has a Profit Margin of 11.54%. This is below the industry average of 16.49%.
VS Industry
ROA (5.91%) VS Industry: 30% outperformed.
0.30
57.39
ROE (16.61%) VS Industry: 50% outperformed.
1.18
180.91
Profit Margin (11.54%) VS Industry: 30% outperformed.
0.20
383.95
Valuation
Valuation Rating
CRL's Price/Earning Ratio is a bit cheaper than the industry average which is at 28.50.
When comparing the Enterprise Value to EBITDA ratio of CRL to the average industry ratio of 20.40, CRL is valued rather cheaply.
With a Price/Earnings Ratio of 23.33, CRL is valued on the expensive side.
With a Forward Price/Earnings Ratio of 21.49, CRL is valued rather expensively.
With a price book ratio of 4.81, CRL is valued correctly.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates CRL does not grow enough to justify the current Price/Earnings ratio.
Compared to an average industry price book ratio of 2.49, CRL is valued more expensive than its industry peers.
VS Industry
Price/Earnings (23.33) VS Industry: 64% outperformed.
111.87
7.60
Price/Book (4.81) VS Industry: 31% outperformed.
52.13
0.34
Enterprise Value/ EBITDA (15.97) VS Industry: 71% outperformed.
666.25
2.34
Growth
Growth Rating
The Earnings Per Share has been growing by 17.72% on average over the past 5 years. This is quite good.
Based on estimates for the next 5 years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.01% on average per year.
CRL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.37%.
The Revenue has been growing by 16.06% on average over the past 5 years. This is quite good.
CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.01%.
CRL is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 9.69% yearly.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 17.72% | 19.72% | 4.01% | 6.48% | 5.74% | 8.62% | 12.01% |
| Revenue | 16.06% | 16.03% | 10.37% | 11.02% | 8.51% | 8.92% | 9.69% |
Health
Health Rating
The Piotroski-F score of CRL is 7.00. This is a strong score and indicates good health and profitability for CRL.
CRL has a Current Ratio of 1.40. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.14 indicates that CRL should not have too much problems paying its short term obligations.
CRL has an Altman-Z score of 2.71. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
CRL has a Altman-Z score comparable to the industry average, which is at 2.71.
Compared to an average industry Current Ratio of 4.77, CRL is worse placed to pay its short term obligations than its industry peers. 84% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 4.30, CRL is worse placed to pay its short term obligations than its industry peers. 84% of its industry peers have a better Quick Ratio.
CRL has one of the worst Debt to Equity ratios in its industry. 89% of its industry peers require less debt for financing their operations.
VS Industry
Debt/Equity (1.12) VS Industry: 11% outperformed.
3.88
0.00
Quick Ratio (1.14) VS Industry: 16% outperformed.
0.04
40.60
Current Ratio (1.4) VS Industry: 16% outperformed.
0.04
40.60
Altman-Z (2.71) VS Industry: 50% outperformed.
-152.45
23.18
Dividend
Dividend Rating
No dividends for CRL!.
CHARLES RIVER LABORATORIES248.21
NYSE:CRL (2/1/2023, 7:07:10 PM)+4.96 (+2.04%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Life Sciences Tools & Services | ||
| Earnings (Last) | 11-02 2022-11-02/bmo | Earnings (Next) | 02-14 2023-02-14 |
| Inst Owners | 195.45% | Inst Owner Change | 0.4% |
| Ins Owners | 0.92% | Ins Owner Change | 0.21% |
| Market Cap | 12.63B | Analysts | 85 |
| Price Target | 271.07 (9.21%) | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS beat(2) | 2 | Avg EPS beat(2) | 2.33% |
| Min EPS beat(2) | 0.3% | Max EPS beat(2) | 4.37% |
| EPS beat(4) | 4 | Avg EPS beat(4) | 1.57% |
| Min EPS beat(4) | 0.26% | Max EPS beat(4) | 4.37% |
| Revenue beat(2) | 1 | Avg Revenue beat(2) | -1.13% |
| Min Revenue beat(2) | -3.17% | Max Revenue beat(2) | 0.92% |
| Revenue beat(4) | 2 | Avg Revenue beat(4) | -0.49% |
| Min Revenue beat(4) | -3.17% | Max Revenue beat(4) | 0.92% |
| PT rev (1m) | -1.3% | PT rev (3m) | -1.94% |
| EPS NQ rev (1m) | 0% | EPS NQ rev (3m) | 0.16% |
| EPS NY rev (1m) | 0% | EPS NY rev (3m) | 0.85% |
| Revenue NQ rev (1m) | 0% | Revenue NQ rev (3m) | 0.03% |
| Revenue NY rev (1m) | 0% | Revenue NY rev (3m) | 0.53% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.33 | ||
| Fwd PE | 21.49 | ||
| P/S | 3.34 | ||
| P/FCF | 45.16 | ||
| P/OCF | 20.56 | ||
| P/B | 4.81 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.97 |
| EPS(TTM) | 10.64 | EY | 4.29% |
| EPS(NY) | 11.55 | Fwd EY | 4.65% |
| FCF(TTM) | 5.5 | FCFY | 2.21% |
| OCF(TTM) | 12.07 | OCFY | 4.86% |
| SpS | 74.32 | BVpS | 51.63 |
| TBVpS | -21.96 | PEG (NY) | 3.6 |
| PEG (5Y) | 1.32 | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.91% | ||
| ROE | 16.61% | ||
| ROIC | 8.65% | ||
| ROICexc | 8.92% | ||
| ROICexgc | 22.67% | ||
| OM | 17.69% | ||
| PM | 11.54% | ||
| GM | 37.31% |
| ROICexgc(3y) | 22.56% | ROICexcg growth 3Y | 3.87% |
| ROICexcg growth 5Y | 3.45% | ROICexc(3y) | 8.64% |
| ROICexc growth 3Y | -1.33% | ROICexc growth 5Y | -2.11% |
| OM growth 3Y | 4.46% | OM growth 5Y | 2.58% |
| PM growth 3Y | 3.4% | PM growth 5Y | 3.71% |
| GM growth 3Y | 0.56% | GM growth 5Y | -0.54% |
| F-Score | 7 | Asset Turnover | 0.51 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.12 | ||
| Debt/FCF | 10.51 | ||
| Debt/EBITDA | 3.05 | ||
| Cap/Depr | 113.94% | ||
| Profit Quality | 64.08% | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 2.71 |
| F-Score | 7 | WACC | 9.35% |
| ROIC/WACC | 2.42 | Cap/Depr(3y) | 76% |
| Cap/Depr(5y) | 75.48% | Profit Quality(3y) | 125.16% |
| Profit Quality(5y) | 139.26% | ||
| EPS 1Y | 4.01% | EPS 3Y | 19.72% |
| EPS 5Y | 17.72% | EPS growth Q2Q | -2.59% |
| EPS Next Y | 6.48% | EPS Next 2Y | 5.74% |
| EPS Next 3Y | 8.62% | EPS Next 5Y | 12.01% |
| Revenue growth 1Y | 10.37% | Revenue growth 3Y | 16.03% |
| Revenue growth 5Y | 16.06% | Revenue growth Q2Q | 10.4% |
| Revenue Next Year | 11.02% | Revenue Next 2Y | 8.51% |
| Revenue Next 3Y | 8.92% | Revenue Next 5Y | 9.69% |
| EBIT growth 1Y | 15.25% | EBIT growth 3Y | 21.2% |
| EBIT growth 5Y | 19.05% | EBIT Next Year | 39.93% |
| EBIT Next 3Y | 19.44% | EBIT Next 5Y | 15.68% |
| FCF growth 1Y | -37.34% | FCF growth 3Y | 21.41% |
| FCF growth 5Y | 15.44% | OCF growth 1Y | 4.3% |
| OCF growth 3Y | 20.26% | OCF growth 5Y | 19.3% |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA